Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
Figure 4
CTX combined with DC-based immunotherapy prolongs survival. Kaplan-Meier survival plot showing the effect of the combination of CTX and DC-based immunotherapy. Mice were given drinking water supplemented with 0.13 mg/ml CTX from day 3 till day 10 and day 14 till day 21. Tumor-lysate-pulsed DCs were given at day 12. Survival significantly improved when CTX and DC-based immunotherapy were combined compared to DC-based immunotherapy () or CTX administration alone (). Each group contained 8 mice.
